Equities

ImpediMed Ltd

ImpediMed Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.054
  • Today's Change0.001 / 1.89%
  • Shares traded2.29m
  • 1 Year change-60.00%
  • Beta2.7151
Data delayed at least 20 minutes, as of Nov 18 2024 04:56 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in AUD

The 4 analysts offering 12 month price targets for ImpediMed Ltd have a median target of 0.150, with a high estimate of 0.19 and a low estimate of 0.09. The median estimate represents a 177.78% increase from the last price of 0.054.
High251.9%0.19
Med177.8%0.150
Low66.7%0.09

Earnings history & estimates in AUD

ImpediMed Ltd reported annual 2024 losses of -0.01 per share on Aug 28, 2024.
Average growth rate+25.00%
More ▼

Revenue history & estimates in AUD

ImpediMed Limited had revenues for the full year 2024 of 10.32m. This was 9.04% below the prior year's results.
Average growth rate+17.61%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.